Recombinant multi-species BCKDHA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCKDHA protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The branched-chain alpha-keto acid (BCAA) dehydrogenase (BCKD) complex is an innter mitochondrial enzyme complex that catalyzes the second major step in the catabolism of the branched-chain amino acids leucine, isoleucine, and valine. The BCKD complex consists of three catalytic components: a heterotetrameric (alpha2-beta2) branched-chain alpha-keto acid decarboxylase (E1), a dihydrolipoyl transacylase (E2), and a dihydrolipoamide dehydrogenase (E3). This gene encodes the alpha subunit of the decarboxylase (E1) component. Mutations in this gene result in maple syrup urine disease, type IA. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]
The Alternative Names of target: 2-oxoisovalerate dehydrogenase subunit alpha,BCKAD,BCKDA,BCKDE1A,BCKDH E1-alpha),BCKDHA,Bckdha,Branched-chain alpha-keto acid dehydrogenase E1 component alpha chain (BCKDE1A,E1[a],E1a,MSU,MSUD1,MSUD1A,OVD1A,mitochondrial

Target products collectionGo to BCKDHA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP10864-Ag-1/ GM-Tg-hg-IP10864-Ag-2 Human BCKDHA protein Human
GM-Tg-rg-IP10864-Ag-1/ GM-Tg-rg-IP10864-Ag-2 Rat BCKDHA protein Rat
GM-Tg-mg-IP10864-Ag-1/ GM-Tg-mg-IP10864-Ag-2 Mouse BCKDHA protein Mouse
GM-Tg-cynog-IP10864-Ag-1/ GM-Tg-cynog-IP10864-Ag-2 Cynomolgus/Rhesus macaque BCKDHA protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP10864-Ag-1/ GM-Tg-felg-IP10864-Ag-2 Feline BCKDHA protein Feline
GM-Tg-cang-IP10864-Ag-1/ GM-Tg-cang-IP10864-Ag-2 Canine BCKDHA protein Canine
GM-Tg-bovg-IP10864-Ag-1/ GM-Tg-bovg-IP10864-Ag-2 Bovine BCKDHA protein Bovine
GM-Tg-equg-IP10864-Ag-1/ GM-Tg-equg-IP10864-Ag-2 Equine BCKDHA protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP10864-Ag-1/ GM-Tg-hg-IP10864-Ag-2; GM-Tg-rg-IP10864-Ag-1/ GM-Tg-rg-IP10864-Ag-2;
GM-Tg-mg-IP10864-Ag-1/ GM-Tg-mg-IP10864-Ag-2; GM-Tg-cynog-IP10864-Ag-1/ GM-Tg-cynog-IP10864-Ag-2;
GM-Tg-felg-IP10864-Ag-1/ GM-Tg-felg-IP10864-Ag-2; GM-Tg-cang-IP10864-Ag-1/ GM-Tg-cang-IP10864-Ag-2;
GM-Tg-bovg-IP10864-Ag-1/ GM-Tg-bovg-IP10864-Ag-2; GM-Tg-equg-IP10864-Ag-1/ GM-Tg-equg-IP10864-Ag-2
Products Name BCKDHA protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name BCKDHA
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCKDHA protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.